Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEONIRenCa neoadjuvant nivolumab plus ipilimumab in high‑risk localized RCC
2021-005949-33Phase 2Terminated
- Sponsor
- University of Cologne
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in renal cell carcinoma (RCC), sponsored by University of Cologne. Primary endpoint: Primary tumor remission rate ≥25%. Started Mar 2022; status: terminated.
02
Drugs
nivolumabipilimumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2021-005949-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005949-33.